144 related articles for article (PubMed ID: 12837985)
21. Tenascin-C in primary malignant melanoma of the skin.
Ilmonen S; Jahkola T; Turunen JP; Muhonen T; Asko-Seljavaara S
Histopathology; 2004 Oct; 45(4):405-11. PubMed ID: 15469480
[TBL] [Abstract][Full Text] [Related]
22. Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival.
Naffouje S; Naffouje R; Bhagwandin S; Salti GI
Melanoma Res; 2015 Dec; 25(6):496-502. PubMed ID: 26317170
[TBL] [Abstract][Full Text] [Related]
23. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit.
McKinnon JG; Yu XQ; McCarthy WH; Thompson JF
Cancer; 2003 Sep; 98(6):1223-31. PubMed ID: 12973846
[TBL] [Abstract][Full Text] [Related]
24. Metallothionein-overexpression as a prognostic factor for progression and survival in melanoma. A prospective study on 520 patients.
Weinlich G; Bitterlich W; Mayr V; Fritsch PO; Zelger B
Br J Dermatol; 2003 Sep; 149(3):535-41. PubMed ID: 14510986
[TBL] [Abstract][Full Text] [Related]
25. Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: a 5-year survival analysis.
Donizy P; Kaczorowski M; Leskiewicz M; Zietek M; Pieniazek M; Kozyra C; Halon A; Matkowski R
Oncol Rep; 2014 Dec; 32(6):2735-43. PubMed ID: 25310673
[TBL] [Abstract][Full Text] [Related]
26. c-Met is a potentially new therapeutic target for treatment of human melanoma.
Puri N; Ahmed S; Janamanchi V; Tretiakova M; Zumba O; Krausz T; Jagadeeswaran R; Salgia R
Clin Cancer Res; 2007 Apr; 13(7):2246-53. PubMed ID: 17404109
[TBL] [Abstract][Full Text] [Related]
27. High LIFr expression stimulates melanoma cell migration and is associated with unfavorable prognosis in melanoma.
Guo H; Cheng Y; Martinka M; McElwee K
Oncotarget; 2015 Sep; 6(28):25484-98. PubMed ID: 26329521
[TBL] [Abstract][Full Text] [Related]
28. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma.
Salti GI; Manougian T; Farolan M; Shilkaitis A; Majumdar D; Das Gupta TK
Cancer Res; 2000 Sep; 60(18):5012-6. PubMed ID: 11016620
[TBL] [Abstract][Full Text] [Related]
29. Gene expression profiling of primary cutaneous melanoma.
Winnepenninckx V; Van den Oord JJ
Verh K Acad Geneeskd Belg; 2007; 69(1):23-45. PubMed ID: 17427873
[TBL] [Abstract][Full Text] [Related]
30. Cytoplasmic Skp2 expression is increased in human melanoma and correlated with patient survival.
Chen G; Cheng Y; Zhang Z; Martinka M; Li G
PLoS One; 2011 Feb; 6(2):e17578. PubMed ID: 21386910
[TBL] [Abstract][Full Text] [Related]
31. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
[TBL] [Abstract][Full Text] [Related]
32. Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study.
Mallikarjuna K; Pushparaj V; Biswas J; Krishnakumar S
Curr Eye Res; 2007 Mar; 32(3):281-90. PubMed ID: 17453948
[TBL] [Abstract][Full Text] [Related]
33. Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma.
Grover R; Chana J; Grobbelaar AO; Hudson DA; Forder M; Wilson GD; Sanders R
Br J Plast Surg; 1999 Mar; 52(2):122-6. PubMed ID: 10434891
[TBL] [Abstract][Full Text] [Related]
34. Expression of Fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival.
Neuber K; Eidam B
Onkologie; 2006 Sep; 29(8-9):361-5. PubMed ID: 16974112
[TBL] [Abstract][Full Text] [Related]
35. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease.
Thies A; Moll I; Berger J; Wagener C; Brümmer J; Schulze HJ; Brunner G; Schumacher U
J Clin Oncol; 2002 May; 20(10):2530-6. PubMed ID: 12011132
[TBL] [Abstract][Full Text] [Related]
36. [Expression of neutral endopeptidase and motility-related protein-1 in cutaneous malignant melanoma].
Wu Y; Zhang XB; Liu HJ; Zheng LD; Li JW; Lin Y
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):466-9. PubMed ID: 17845760
[TBL] [Abstract][Full Text] [Related]
37. BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases.
Eriksson H; Zebary A; Vassilaki I; Omholt K; Ghaderi M; Hansson J
JAMA Dermatol; 2015 Apr; 151(4):410-6. PubMed ID: 25588152
[TBL] [Abstract][Full Text] [Related]
38. Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma.
Hoersch B; Leiter U; Garbe C
Br J Dermatol; 2006 Oct; 155(4):771-7. PubMed ID: 16965427
[TBL] [Abstract][Full Text] [Related]
39. Comparison of metallothionein-overexpression with sentinel lymph node biopsy as prognostic factors in melanoma.
Weinlich G; Topar G; Eisendle K; Fritsch PO; Zelger B
J Eur Acad Dermatol Venereol; 2007 May; 21(5):669-77. PubMed ID: 17447982
[TBL] [Abstract][Full Text] [Related]
40. KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients.
Janku F; Novotny J; Julis I; Julisova I; Pecen L; Tomancova V; Kocmanova G; Krasna L; Krajsova I; Stork J; Petruzelka L
Melanoma Res; 2005 Aug; 15(4):251-6. PubMed ID: 16034302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]